Isotope Technologies Munich SE: ITM and Clovis Oncology Announce Lutetium-177 Clinical Supply Agreement

ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Clovis Oncology's Targeted Radionuclide Therapy candidate FAP-2286 ITM Isotope Technologies

Related Keywords

Colorado ,United States ,Boulder ,Munich ,Bayern ,Germany ,Russia ,Israel ,Turkey ,Susanne Karlsson ,Patrick Mahaffy ,Lu Endolucinbeta ,Julia Hofmann ,Valeria Fisher ,Steffen Schuster ,Anna Sussman ,Jake Davis ,Lisa Guiterman ,Breanna Burkart ,Exchange Commission ,Clovis Oncology Inc ,Pb Pharmaceuticals ,Deputy Head Of Corporate Communications ,Trophic Communications ,Head Of Corporate Communications ,Nasdaq ,Clovis Oncology ,Targeted Radionuclide Therapy ,Technologies Munich ,Targeted Radionuclide Therapies ,Activity Reference Time ,Radionuclide Therapy ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Corporate Communications ,Deputy Head ,Media Contacts ,Isotope ,Technologies ,Lovis ,Ncology ,Nnounce ,Lutetium ,Linical ,Supply ,Agreement ,